<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38608516</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-0356</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Multiple sclerosis and related disorders</Title><ISOAbbreviation>Mult Scler Relat Disord</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population.</ArticleTitle><Pagination><StartPage>105613</StartPage><MedlinePgn>105613</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.msard.2024.105613</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-0348(24)00192-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although certain subsets patients with multiple sclerosis (MS), an immune-mediated disorder, are at higher risk of worse acute COVID-19 outcomes compared to the general population, it is not clear whether SARS-CoV-2 infection impacts long-term outcomes compared with MS patients without COVID-19 infection.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study investigated MS disease activity and mortality 3.5 years post SARS-CoV-2 infection and compared with MS patients without COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study evaluated 1,633 patients with MS in the Montefiore Health System in the Bronx from January 2016 to July 2023. This health system serves a large minority population and was an epicenter for the early pandemic and subsequent surges of infection. Positive SARS-CoV-2 infection was determined by a positive polymerase-chain-reaction test. Primary outcomes were all-cause mortality, and optic neuritis post SARS-CoV-2 infection. Secondary outcomes included change in disease-modifying therapy (DMT), treatment with high-dose methylprednisolone, cerebellar deficits, relapse, and all-cause hospitalization post-infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">MS patients with COVID-19 had similar demographics but higher prevalence of pre-existing major comorbidities (hypertension, type-2 diabetes, chronic obstructive pulmonary disease, congestive heart failure, chronic kidney disease, and coronary artery disease), optic neuritis, and history of high dose steroid treatment for relapses compared to MS patients without COVID-19. MS patients with COVID-19 had greater risk of mortality (adjusted HR=4.34[1.67, 11.30], p &lt; 0.005), greater risk of post infection optic neuritis (adjusted HR=2.97[1.58, 5.58], p &lt; 0.005), higher incidence of methylprednisolone treatment for post infection acute relapse (12.65% vs. 2.54 %, p &lt; 0.001), and more hospitalization (78.92% vs. 66.81 %, p &lt; 0.01), compared to MS patients without COVID-19.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MS patients who survived COVID-19 infection experienced worse long-term outcomes, as measured by treatment for relapse, hospitalization and mortality. Identifying risk factors for worse long-term outcomes may draw clinical attention to the need for careful follow-up of at-risk individuals post-SARS-CoV-2 infection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hadidchi</LastName><ForeName>Roham</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; Center for Health &amp; Data Innovation, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Stephen H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; Center for Health &amp; Data Innovation, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezko</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; Center for Health &amp; Data Innovation, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Sonya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; Center for Health &amp; Data Innovation, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coyle</LastName><ForeName>Patricia K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Tim Q</ForeName><Initials>TQ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; Center for Health &amp; Data Innovation, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA. Electronic address: tim.duong@einsteinmed.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mult Scler Relat Disord</MedlineTA><NlmUniqueID>101580247</NlmUniqueID><ISSNLinking>2211-0348</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009902" MajorTopicYN="N">Optic Neuritis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014505" MajorTopicYN="N">Urban Population</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009519" MajorTopicYN="N" Type="Geographic">New York City</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinically isolated syndrome</Keyword><Keyword MajorTopicYN="N">Disease modifying therapy</Keyword><Keyword MajorTopicYN="N">Hyperinflammation</Keyword><Keyword MajorTopicYN="N">Long covid</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of covid-19 (PASC)</Keyword><Keyword MajorTopicYN="N">Radiologically isolated syndrome</Keyword></KeywordList><CoiStatement>Declaration of competing interest Patricia K. Coyle has received consultant and/or speaker fees from Accordant, Biogen, Bristol Myers Squibb, Celgene, Genentech/Rochem GlaxoSmithKline, Janssen, Novartis, Sanofi, Genzyme, and Viela Bio. Dr. Coyle has also received grant/research support from Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, and Novartis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>9</Day><Hour>0</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>13</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>12</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38608516</ArticleId><ArticleId IdType="doi">10.1016/j.msard.2024.105613</ArticleId><ArticleId IdType="pii">S2211-0348(24)00192-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>